The Latest
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
AbbVie’s $10.9 billion acquisition of Apogee Therapeutics is the year’s second-largest biotech buyout and the company’s biggest since its $63 billion takeover of Allergan in 2019.
Updated June 22, 2026 -
Permission granted by Alkermes
Q&AAlkermes’ incoming CEO has a plan to outplay Lilly and Takeda
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
-
Getty Images
Viridian may have edge over Amgen in eye drug showdown, analysts argue
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
-
ASCO / Nick Agro
The top biopharma conferences remaining in 2026
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch the rest of 2026.
Updated June 25, 2026 -
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
This year’s IPO class has already accounted for five of the six largest new biotech stock offerings since the start of 2022, according to BioPharma Dive data.
Updated June 17, 2026 -
Getty Images
News roundupIpsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
-
Getty Images
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
-
Getty Images
Brain drug revivalTo Wall Street, psychedelics biotechs are more teammates than rivals
Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic field and “bring it even further into the mainstream.”
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Immune drugmakers carried the majority of venture financing in the second half of June, bringing in $608 million in total across five companies, according to BioPharma Dive data.
Updated June 30, 2026 -
Getty Images
IPO window‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitting a certain criteria.
-
Michael M. Santiago via Getty Images
Q&A // Emerging biotechHow Kardigan spun deal leftovers into a $400M IPO
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.
-
Alamy
Beeline ups its Series A round for immune drug work
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.
Updated June 1, 2026 -
Getty Images
News roundup
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
-
Getty Images
On second try, Acadia drug gets nod from European regulators
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
-
Sarah Silbiger via Getty Images
Ionis, with new FDA nod, hits a ‘commercial inflection point’
Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar medicine in Tryngolza, which secured expanded approval Wednesday.
-
Getty Images
Remix to go public in reverse merger with once high-flying Passage Bio
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
-
Getty Images
Antares gets $105M from Novartis for new cancer drugs
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."
-
Getty Images
Emerging biotech
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.
-
NIAID. (2023). "Influenza A virus" [Micrograph]. Retrieved from Flickr.
Emerging biotechInvestors pour $115M into RQ Bio in search of a preventive flu drug
The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.
-
Getty Images
News roundup
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.
-
Getty Images
China competitionHHS, responding to China’s rise, moves to fast-track early drug research
A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.
-
Jeenah Moon via Getty Images
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
-
Alamy
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.
-
Getty Images
News roundup
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.
